Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Glucagon-like
100%
Associated Complications
100%
Dipeptidyl peptidase-4 (DPP-4)
100%
Placebo
92%
Liraglutide
57%
Placebo Groups
35%
Exenatide
28%
Vildagliptin
28%
Review Authors
28%
Randomized Controlled Trial
21%
Serious Adverse Events
21%
Liraglutide 3.0 Mg
21%
Confidence Interval
14%
Meta-analysis
14%
Nonfatal Myocardial Infarction
14%
Impaired Glucose Tolerance
14%
Hemoglobin A1c (HbA1c)
14%
Monotherapy
14%
Congestive Heart Failure
14%
Socio-economic Impact
14%
Normoglycaemia
14%
Impaired Fasting Glucose
14%
World Health Organization
14%
Risk of Bias
14%
Cardiovascular Mortality
7%
Low Risk
7%
36-item Short Form
7%
Health-related Quality of Life
7%
Embase
7%
Plasma Glucose
7%
Vascular Complications
7%
Am(III)
7%
PubMed
7%
All-cause Mortality
7%
Health Technology Assessment
7%
MEDLINE
7%
Risk Ratio
7%
Extracted Data
7%
Fasting Plasma Glucose
7%
Glucose-lowering Drugs
7%
Diagnostic Criteria
7%
Cochrane Central Register of Controlled Trials
7%
Health Problems
7%
Random Effects Model
7%
Behavior Change
7%
Glycated Hemoglobin A1c
7%
Type 2 Diabetes Mellitus Risk
7%
Effect Estimates
7%
Off-treatment
7%
Metformin Monotherapy
7%
Continuous Outcomes
7%
Treatment Cessation
7%
Dichotomous Outcomes
7%
Physical Components
7%
Life Effects
7%
Assessment Report
7%
Patient-important Outcomes
7%
International Clinical Trials Registry Platform (ICTRP)
7%
Short-form Scales
7%
People at Risk
7%
Comparator Group
7%
January 2017
7%
Intermediate Hyperglycemia
7%
Medicine and Dentistry
Placebo
100%
Maturity Onset Diabetes of the Young
100%
Glucagon Like Peptide 1
100%
Dipeptidyl Peptidase-4 Inhibitor
100%
Liraglutide
61%
Arm
33%
Exenatide
22%
Vildagliptin
22%
Adverse Event
16%
Randomized Controlled Trial
16%
Hemoglobin A1c
16%
Monotherapy
16%
Myocardial Infarction
11%
Meta-Analysis
11%
Impaired Glucose Tolerance
11%
Apoplexy
11%
Congestive Heart Failure
11%
Disease
5%
Diagnosis
5%
Quality of Life
5%
Systematic Review
5%
Microvascular Complication
5%
Glycon
5%
Clinical Trial
5%
Technology Assessment
5%
Health Technology
5%
All Cause Mortality
5%
Hyperglycemia
5%
Blood Glucose
5%
Cardiovascular Mortality
5%
Random Effects Model
5%
Impaired Fasting Glucose
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon-Like Peptide-1
100%
Dipeptidyl Peptidase IV Inhibitor
100%
Liraglutide
61%
Exendin 4
22%
Vildagliptin
22%
Adverse Event
16%
Randomized Controlled Trial
16%
Hemoglobin A1c
16%
Monotherapy
16%
Heart Infarction
11%
Congestive Heart Failure
11%
Impaired Glucose Tolerance
11%
Disease
5%
Metformin
5%
Clinical Trial
5%
All Cause Mortality
5%
Cardiovascular Mortality
5%
Hyperglycemia
5%
Random Effects Model
5%